Fatigue In Relapsing Multiple Sclerosis – Epstein Barr Virus (FIRMS-EBV) Treatment Trial
Fatigue is a common symptom for many people with MS and it does not respond to traditional MS treatments. It has been suggested that fatigue in MS could relate to chronic infection with the Epstein Barr Virus (EBV). In this clinical trial, two drug therapies with antiviral effects against EBV will be tested for their […]
Phase III, multicentre, randomised, double-blinded, placebo-controlled, MAMS trial of SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression (STOP-MS)
Multiple sclerosis (MS) is a potentially devastating disease of the central nervous system and progressive MS, which occurs in up to two-thirds is the most severe form. Current therapies for MS have limited effect in the progressive stage. Recent studies have confirmed that the primary cause of MS is latent infection with Epstein-Barr virus (EBV). […]
A randomized, double-blind, Phase 3 study comparing efficacy and safety of SAR441344 to placebo in adult participants with non-relapsing secondary progressive multiple sclerosis (FREVIVA)
This is a Phase 3 clinical trial. Its aim is to demonstrate the efficacy and safety of an investigational drug compared to placebo in participants with Secondary Progressive MS. Globally, approximately 868 participants will be randomly assigned to the investigational drug or placebo. This is a double-blind study. This means the study doctor and participant […]
Light Therapy for Fatigue and Daytime Sleepiness in Multiple Sclerosis
Fatigue and excessive daytime sleepiness are common complaints in individuals living with multiple sclerosis (MS). Fatigue and excessive daytime sleepiness are associated with the emergence and exacerbation of cognitive, motor and mood disturbances and over time lead to impaired rehabilitation outcomes, a decline in the capacity to perform daily activities and reduced quality of life. […]